NL-OMON35247已完成不适用
Single-center, double-blind, randomized, placebo-controlled, single-ascending dose and food interaction study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-389949 in healthy male subjects - ACT-389949
Actelion Pharmaceuticals0 个研究点目标入组 64 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy Caucasian male subject
排除标准
- •Clinically significant abnormalities at screening
研究者
相似试验
尚未招募
不适用
Clinical studies to evaluate the efficacy and safety of oxygen / ozone therapy devices for patients suffering from pain due to lumbar disc herniatioKCT0003917Healthwell Medical50
进行中（未招募）
1 期
Refractory abdominal fluid (ascites) in patients with liver cirrhosis, and the potential treatment with 48 hours infusion of ularitide; a salt and water excreting peptide.iver cirrhosis with refractory ascites.MedDRA version: 20.0Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.0Level: PTClassification code 10003445Term: AscitesSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-002268-28-DKDepartment of Hepatology and Gastroenterology, Aarhus University Hospital38
进行中（未招募）
不适用
Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fibrosis homozygous for the F508del mutatioCystic fibrosis homozygous for the F508del mutationMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2008-002352-20-BEActelion Pharmaceuticals Ltd
已完成
不适用
Clinical trial for evaluation of efficacy on cognitive function of MT104Mental and behavioural disordersKCT0006499Kyung Hee University Hospital86
已完成
不适用
Metabolic drug interaction profile of Silexan in vivoActivities of cytochrome P-450 enzymesISRCTN74386009Dr. Willmar Schwabe GmbH & Co. KG (Germany)16